Today in Peak History (September 1-10)
Release time:
2020-08-14
peak (# March - 10 )
1959 9 , the original Tangxi cement plant was canceled and more than 30 employees were merged into Jinhua cement plant.
1964 9 , with the approval of Zhejiang Provincial Planning Commission, Jinhua Cement Plant resumed production by ignition of two general kilns that had been shut down for two years.
◆ 1978 9 March, Zhejiang Building Materials Industry Bureau awarded Jinhua Cement Factory the title of "Enterprise with Outstanding Achievements in Industry Daqing.
◆ 1989 9 January, the internal journal sponsored by Jianfeng Group-"Jianfeng" quarterly was launched.
◆ 1997 9 , Jianfeng Group and Hangzhou Pharmaceutical Research Institute jointly established Hangzhou Jianfeng Dekang Pharmaceutical Co., Ltd., taking another solid step towards the pharmaceutical industry.
1998 9 In September, Du Zihong, then chairman of the group company, was awarded the title of "Outstanding Contribution Enterprise Operator" in Zhejiang Province.
◆ 2000 9 July 8 , in Ruoyang Township, known as "Jinhua Little Tibet", the teaching building of Jianfeng Hope Primary School was completed and opened.
2001 9 In September, the Jianfeng Group donated 20 yuan to build the Jianfeng Hope Primary School in Moyu County, Xinjiang, which was put into use. The love of the Jianfeng people who donated money to help students was transmitted to the distant southern Xinjiang.
2003 9 In August, the trade union of Jianfeng Group Company won the title of "National Model Workers' Home.
2005 9 July, Jiang Xiaomeng, general manager of the group company, was approved by the State Council and enjoyed special government subsidies.
2009 9 05 3 , at the 8th member representative meeting of Jinhua Enterprise Federation and Jinhua Entrepreneurs Association, Jiang Xiaomeng, chairman of the group company, was elected president of the new Jinhua Entrepreneurs Association, and Du Zihong, former chairman of the group company, was appointed honorary president by the council of the two sessions.
2009 May 8 , the plant extraction workshop project of Jianfeng Pharmaceutical Company officially started construction and was completed at the end of December 11 September .
July , Jianfeng Pharmaceutical Company obtained a utility model patent for cefmenoxime micronization device.
2011 July, Zhejiang Province and Jinhua City successively held a commendation meeting for the 139 anniversary of the implementation of the Hope Project . Jianfeng Group was commended for its enthusiasm for public welfare and continuous donation to teaching assistants over the years.
July, Jianfeng Pharmaceutical Company won the title of "Zhejiang Innovative Demonstration Enterprise" and was shortlisted in "Top 100 Chinese Pharmaceutical Enterprises".
May 7 , Zhejiang Jianfeng Biotechnology Co., Ltd. was officially registered and established, which marked a solid step forward for Jianfeng Group to the big health industry.
September May, Jianfeng International Trading Company was designated by Dalian Commodity Exchange as the designated delivery warehouse for plywood and polypropylene (PP ) futures. ◆
September 17 May, Jianfeng Group won the "Zhejiang Industrial Award Silver Award" of 2016 ". ◆ 2017
9 May, daye peak won the title of "Best Honest Enterprise" in daye city. This is the city's first selection, recognition of integrity enterprises. (Xu Xia finishing)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page